A new oral medication, REYVOW™ (lasmiditan) has been launched by Eli Lilly and Company for the treatment of acute migraine, with or without aura, in adults.
The drug, REYVOW is delivered orally via a tablet and is the first serotonin receptor agonist. It binds to (5-HT) 1F receptor with high affinity.
However, its exact mechanism is unknown yet.
The effectiveness of REYVOW was demonstrated in two randomized, double-blind, placebo-controlled trials.
In both the studies, the percentage of patients whose pain had resolved was significantly greater for those taking the medication rather than the placebo.
The treatment-emergent adverse events in the trial were generally mild to moderate and the most frequent included fatigue, dizziness, nausea and/or vomiting, paresthesia, sedation, and muscle weakness.
REYVOW can be prescribed to patients in oral doses of 50mg, 100mg, and 200mg as needed and once available.
The US FDA has given its approval for the drug.
